Trendlines Establishes China-Based China-Israel New Trend with Shoushan Wealth Holdings

JV will assist Trendlines' and other Israeli and Singaporean medical device companies with commercialization, manufacturing and other activities in China. Parties to raise venture funds to invest in medical companies.

MISGAV, Israel - SHANGHAI, China - 21 August 2017 -- The Trendlines Group Ltd. ("**Trendlines**") (SGX: 42T; OTCQX: TRNLY), an Israeli and Singapore-based investment and innovation commercialization company focused on early-stage innovation-based medical and agricultural technologies, with offices in Israel, Singapore, and China, and Shoushan Wealth Holdings ("**Shoushan**"), a Chinese private equity investment, investment banking, funds management and financial services company, jointly announced the signing of the Definitive Agreement to establish and manage China-Israel New Trend (Taizhou) Medical Technology Co. Ltd., a Shanghai-based Joint Venture ("**the JV**") to help Trendlines' medical sector portfolio companies and other Israeli, Singaporean and other medical companies penetrate the Chinese market. The JV will be held 51% by Trendlines and 49% by Shoushan.

The JV, for which execution of the term sheet was announced on 16 December 2016, is headquartered in Shanghai with additional staff in Israel. The JV will provide services to select Israeli, Singaporean and other medical device companies, including support in establishing manufacturing capabilities in China, obtaining regulatory approval for sale of products in China, and managing strategic partner relationships. The core of the JV's business model is to facilitate the establishment of new manufacturing and commercialization partnerships for the Israeli, Singaporean and other medical device companies.

Trendlines and Shoushan (the "**Parties**") intend to raise US dollar and Chinese RMB venture funds (the "**Funds**"), which they will manage, to invest in Trendlines' portfolio companies and other Israeli, Israel-related, Singaporean and other medical device companies. The parties intend to offer a combination of financial investment by the Funds and assistance in penetrating China through the JV.

Todd Dollinger, Trendlines' Chairman and CEO, said: "Trendlines views the Chinese market as critical to maximizing the success of our portfolio companies and the agreement with Shoushan is central to supporting and developing our companies in China. We have been working in China for some five years; our first Chinese employee, Eddy Wang, joined us as Director of our China Office three years ago. We have been patient in building our China-based business; in Shoushan – with which we have spent more than a year developing our relationship and modus operandi – we have found a partner with which we share common values. Our work with Shoushan is part of Trendlines' dedication to and active involvement in our portfolio companies."

Mr. Zhang Jun, CEO of Shoushan, commented: “Being deeply networked in the Chinese economy, Shoushan sees the opportunity in China for innovative medical solutions, but also the challenges that foreign companies experience in penetrating our market. The Shoushan/Trendlines JV and Trendlines will engage the best innovative medical technology companies and offer, through the combined strengths of our JV, a unique way into China, thus creating tremendous value for all.”

About Shoushan Wealth Management:

Shoushan Wealth Holdings is part of the Shoushan Wealth Management Group, a leading wealth management service provider in China, providing all-around comprehensive wealth-management service for high net-worth individuals, families and enterprises. The group is headquartered in Shanghai and operates centers in Shenzhen, Beijing and other locations in China. The group employs about 100 professionals in the fields of tax, finance, law, securities, investment banking and capital management.

About The Trendlines Group

The Trendlines Group is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural companies to fulfil its mission to improve the human condition. As an intensely hands-on investor, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines is traded on the Singapore Stock Exchange (SGX: 42T) and in the United States on the OTCQX (OTCQX: TRNLY).

Investor Contact Information

Israel:
Judith Kleinman, Director, Investor Relations & Corporate Communications
The Trendlines Group
judith@trendlines.com
Tel: +972.72.260.7000

Singapore and China:
Reyna MEI
Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).